Among some examples, we should highlight the impact of endocrine therapy for ER+ tumours using aromatase inhibitors or tamoxifen, or the antibody herceptin/trastuzumab for tumours showing HER2+ overexpression [14]. This evidence concerns the gene CYP19A1 and neoplasm.